■ 英語タイトル：Diabetic Retinopathy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
	■ 発行会社/調査会社：IMARC ■ 商品コード：IMARC23AP148 ■ 発行日：2023年2月21日    最新版(2025年又は2026年)版があります。お問い合わせください。 ■ 調査対象地域：グローバル ■ 産業分野：医療 ■ ページ数：142 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール

The global diabetic retinopathy market size reached US$ 7.6 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 10.8 Billion by 2028, exhibiting a growth rate (CAGR) of 6.1% during 2023-2028.

Diabetic retinopathy (DR) refers to the damage caused to the blood vessels in the retina by diabetes mellitus. This ailment is of two kinds, namely non-proliferative DR and proliferative or advanced DR. It is caused by fluctuations in the blood glucose levels resulting in an abnormal growth in the light-sensitive tissues present in the eye. The symptoms of DR include the visibility of dark spots or floating strings in the vision field, blurred or fluctuating vision, impaired color vision or loss of vision. It can be diagnosed through tests, such as fluorescein angiography and optical coherence tomography, and the treatment involves the use of intraocular steroid injection, laser treatment and vitrectomy.

The increasing prevalence of diabetes, along with the growing geriatric population across the globe, represent as the key factors driving the growth of the market. Furthermore, the rising incidence of blindness caused by DR is also providing a boost to the market growth. There is an increasing awareness among the masses regarding the available treatment alternatives and the benefits of early detection of DR. This has resulted in the widespread adoption of technologically advanced procedures and equipment, such as the improved ophthalmic diagnostic and surgical instruments. These procedures and equipment enable early detection and efficient treatment of the ailment with higher precision and minimal discomfort to the patient. Other factors, including the increasing healthcare expenditures, the implementation of favorable government policies to make advanced healthcare services available to the masses and extensive research and development (R&D) activities, are projected to drive the market further.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global diabetic retinopathy market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, treatment type and end-user.

Breakup by Type:
Proliferative Diabetic Retinopathy
Non-proliferative Retinopathy

Breakup by Treatment Type:
Anti VEGF Drugs
Steroid Implants
Laser Surgeries
Vitrectomy

Breakup by End-User:
Hospitals and Pharmacies
Eye Clinics
Ambulatory Surgical Centres (ASCs)
Others

Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined with some of the key players being Alimera Sciences, Allergan PLC, Ampio Pharmaceuticals, Bayer Healthcare, BCN Peptides, Genentech, Kowa Group, Novartis AG, Regeneron Pharmaceuticals Inc., Sirnaomics Inc., etc.

Key Questions Answered in This Report:
How has the global diabetic retinopathy market performed so far and how will it perform in the coming years?
What are the key regional markets?
What has been the impact of COVID-19 on the global diabetic retinopathy market?
What is the breakup of the market based on the type?
What is the breakup of the market based on the treatment type?
What is the breakup of the market based on the end-user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global diabetic retinopathy market and who are the key players?
What is the degree of competition in the industry?